VERTEX PHARMACEUTICALS INC / MA VRTX

Vertex Pharmaceuticals' strongest current evidence is the March quarter financial filing: revenue from contracts with customers was $2.99B, net income attributable to parent was $1.03B, operating income was $1.14B and diluted EPS was $4.02 for the period ending 2026-03-31, according to the 10-Q filed on SEC EDGAR.

The company is being read here as an operating pharmaceutical business, not a loose ticker story. The product evidence matters because the 10-Q says ALYFTREK net product revenues have totalled $1.3B since inception and CASGEVY product revenues were $43M in the first quarter of 2026. Those figures connect the market file to named commercial products rather than vague pipeline language.

The balance sheet rail is also substantial. The same 10-Q lists assets of $26.48B, liabilities of $7.12B, stockholders' equity attributable to parent of $19.36B, cash and cash equivalents of $5.49B, net cash provided by operating activities of $1.43B, payments to acquire property, plant and equipment of $133.4M, inventory net of $1.77B and an inventory increase of $97.7M for the period ending 2026-03-31. Weighted average diluted shares outstanding were 256.3M.

The supplied source rail does not include a chart route or quoted trading levels, so the market mechanism has to stay with public filings and product economics. The useful context is the contrast between a profitable, cash-generative quarter and the live filing trail: Form 144 filings dated 2026-06-18, 2026-06-15 and 2026-06-05, and Form 4 filings dated 2026-06-17, 2026-06-09 and 2026-06-03, all from SEC EDGAR.

Governance is part of the current file. A 2026-05-13 8-K says the Board approved the Vertex Pharmaceuticals Incorporated 2026 Stock and Option Plan on 2026-03-27, replacing the 2013 Stock and Option Plan. That does not prove anything about future performance, but it does put incentives, dilution optics and executive compensation machinery into the same public evidence bundle as the revenue and product story.

The limit is also clear. The evidence supplied proves latest parsed financials, named product revenue facts and recent SEC filing trail. It does not provide guidance, a dividend, a buyback figure, segment pressure beyond the named product facts, price action, analyst revisions, trial readouts, regulatory approvals beyond the listed filing text, or chart levels. A deeper file would need those source rails before making stronger market claims.